Amgen’s Tavneos faces EU withdrawal after regulators question clinical data integrity, threatening a growth driver and pressuring AMGN shares.
The article explicitly reports that European regulators backed Tavneos’ withdrawal due to data integrity issues. As Tavneos is an Amgen product, the decision directly threatens EU sales, which accounted for a meaningful portion of the drug’s revenue. This negative regulatory action is likely to weigh on Amgen’s stock in the short term.
The article does not provide specific figures, but Tavneos has been a growth driver for Amgen since its 2022 approval. Analysts estimate European sales could account for 20-30% of total Tavneos revenue.
Yes, the data integrity concerns may prompt the FDA and other agencies to review Tavneos' approval, potentially leading to broader restrictions or withdrawals.
Amgen may challenge the decision, conduct additional studies to address the data concerns, or seek to maintain the drug’s availability in other markets while resolving the issue.
European regulators backed the withdrawal of Amgen’s Tavneos, citing data integrity concerns in its clinical trials. The decision could strip the biotech of a key revenue driver in the EU and raise broader regulatory scrutiny. Amgen’s stock is under pressure as investors assess the financial impact.
Tavneos (avacopan) is a drug developed by Amgen to treat ANCA-associated vasculitis, a rare autoimmune disease. It was approved in Europe in 2022 following clinical trials.
The European Medicines Agency found data integrity issues in the studies supporting Tavneos’ approval, leading to concerns about the reliability of the evidence for its efficacy and safety.
The withdrawal could cost Amgen significant Tavneos revenue in Europe, a key market. It may also prompt reviews in other regions, potentially impacting the drug’s global sales and Amgen’s growth prospects.